Biblio
“Acute Stroke Care in Dementia: A Cohort Study from the Swedish Dementia and Stroke Registries.”, J Alzheimers Dis, vol. 66, no. 1, pp. 185-194, 2018.
, “Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?”, J Alzheimers Dis, vol. 52, no. 2, pp. 417-20, 2016.
, “Assessment and Reporting of Driving Fitness in Patients with Dementia in Clinical Practice: Data from SveDem, the Swedish Dementia Registry.”, J Alzheimers Dis, vol. 53, no. 2, pp. 631-8, 2016.
, “Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers.”, J Alzheimers Dis, vol. 53, no. 2, pp. 621-30, 2016.
, “BDNF Responses in Healthy Older Persons to 35 Minutes of Physical Exercise, Cognitive Training, and Mindfulness: Associations with Working Memory Function.”, J Alzheimers Dis, vol. 55, no. 2, pp. 645-657, 2017.
, “Behavioral and Psychological Symptoms of Dementia in Different Dementia Disorders: A Large-Scale Study of 10,000 Individuals.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1307-1318, 2022.
, “Bisecting N-Acetylglucosamine Correlates with Phospho-Tau181 in Subjective Cognitive Decline but not in Control Cases.”, J Alzheimers Dis, 2024.
, “Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.”, J Alzheimers Dis, vol. 83, no. 4, pp. 1703-1715, 2021.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.”, J Alzheimers Dis, vol. 83, no. 3, pp. 1149-1159, 2021.
, “Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1477-1487, 2017.
, “Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe.”, J Alzheimers Dis, vol. 60, no. 1, pp. 201-210, 2017.
, “Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 57, no. 2, pp. 387-393, 2017.
, “A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 4, pp. 1163-1174, 2019.
, “Living Alone with Alzheimer's Disease: Data from SveDem, the Swedish Dementia Registry.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1265-1272, 2017.
, “Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort.”, J Alzheimers Dis, vol. 57, no. 3, pp. 787-795, 2017.
, “Mortality After Ischemic Stroke in Patients with Alzheimer's Disease Dementia and Other Dementia Disorders.”, J Alzheimers Dis, vol. 81, no. 3, pp. 1253-1261, 2021.
, “Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 1, pp. 349-61, 2016.
, “The Relationship Between Cardiovascular Health and Rate of Cognitive Decline in Young-Old and Old-Old Adults: A Population-Based Study.”, J Alzheimers Dis, vol. 84, no. 4, pp. 1523-1537, 2021.
, “A Super-Resolved View of the Alzheimer's Disease-Related Amyloidogenic Pathway in Hippocampal Neurons.”, J Alzheimers Dis, vol. 83, no. 2, pp. 833-852, 2021.
, “Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.”, J Alzheimers Dis, vol. 83, no. 1, pp. 355-366, 2021.
, “Treatment of Atrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1119-1128, 2018.
,